CRP and metabolic syndrome: In the current study, we tested the metabolic and renoprotective effects of empagliflozin in spontaneously hypertensive rats expressing human C-reactive protein (SHR-CRP rats), a non-diabetic model of metabolic syndrome with severe hypertension, systemic inflammation, metabolic and hemodynamic disturbances, and target organ injury [19].